Regulatory PathRegulatory requirements compared

Active substance

Somatropin

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
GENOTROPIN 16IU CARTRIDGE16 IUPowder and solvent for solution for injection · Subcutaneous use1 CartridgeSAR 385.70Biological · PrescriptionPFIZER SAValid
GENOTROPIN GOQUICK 12MG PRE-FILLED PEN12 mgPowder and solvent for solution for injection · Subcutaneous use1 Pre-filled penSAR 869.70Biological · PrescriptionPFIZER SAValid
Genotropin GoQuick 5.3 mg5.3 mgPowder and solvent for solution for injection · Subcutaneous use1 Pre-filled penSAR 384.10Biological · PrescriptionPFIZER SAValid
Norditropin FlexPro3.3 mg/mlSolution for injection in pre-filled pen · Subcutaneous use1 Pre-filled penSAR 489.60Biological · PrescriptionNOVO NORDISKValid
Norditropin FlexPro6.7 mg/mlSolution for injection in pre-filled pen · Subcutaneous use1 Pre-filled penSAR 975.90Biological · PrescriptionNOVO NORDISKValid
Norditropin FlexPro10 mg/mlSolution for injection in pre-filled pen · Subcutaneous use1 Pre-filled penSAR 1463.90Biological · PrescriptionNOVO NORDISKValid
OMNITROPE 3.3 MG/ML Solution for injection in cartridge3.3 mg/mlSolution for injection in cartridge · Subcutaneous use5 CartridgeSAR 2004.95Biological · PrescriptionSANDOZValid
OMNITROPE 6.7 MG/ML Solution for injection in cartridge6.7 mg/mlSolution for injection in cartridge · Subcutaneous use5 CartridgeSAR 4009.95Biological · PrescriptionSANDOZValid
Saizen6 mgSolution for injection in cartridge · Subcutaneous use1 CartridgeSAR 512.85Biological · PrescriptionMERCK SERONO EUROPE LTDValid
Saizen12 mgSolution for injection in cartridge · Subcutaneous use1 CartridgeSAR 1025.70Biological · PrescriptionMERCK SERONO EUROPE LTDValid
GENOTROPIN 36 IU CARTRIDGE36 IUPowder and solvent for solution for injection · Subcutaneous use1 CartridgeSAR 1121.30Biological · PrescriptionOCTAPHARMAWithdrawn by MAH · Not Marketed
GENOTROPIN 4IU INJECTION4 IUPowder and solvent for solution for injection · Subcutaneous use1 VialSAR 94.90Biological · PrescriptionPFIZERWithdrawn by MAH · Not Marketed
HUMATROPE 4 IU VIAL I-M OR S-C4 IUPowder for injection · Subcutaneous use1 VialSAR 130.20Biological · PrescriptionEli Lilly and CompanyWithdrawn by MAH · Not Marketed
NORDITROPIN 12 I.U PENSET12 IUSolution for injection · Subcutaneous use1 VialSAR 371.70Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN 12 I.U VIAL12 IUSolution for injection · Subcutaneous use1 VialSAR 337.90Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN 24 I.U PENSET24 IUSolution for injection · Subcutaneous use1 VialSAR 743.40Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN 4 I.U VIAL4 IUInjection · Subcutaneous use1 VialSAR 117.30Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN NORDIFLEX 10MG\1.5ML CARTRIDGE10 mgSolution for injection · Subcutaneous use1 CartridgeSAR 1003.20Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN NORDIFLEX 15MG\1.5ML CARTRIDGE15 mgSolution for injection · Subcutaneous use1 CartridgeSAR 1504.85Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN NORDIFLEX 5MG\1.5ML CARTRIDGE5 mgSolution for injection · Subcutaneous use1 CartridgeSAR 503.30Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN NORDILET 10MG\1.5ML10 mgSuspension for injection in pre-filled pen · Subcutaneous use1 CartridgeSAR 955.45Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN NORDILET 15MG\1.5ML15 mgSuspension for injection in pre-filled pen · Subcutaneous use1 CartridgeSAR 1433.20Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
NORDITROPIN NORDILET 5MG\1.5ML5 mgSuspension for injection in pre-filled pen · Subcutaneous use1 CartridgeSAR 479.35Biological · PrescriptionNOVO NORDISKWithdrawn by MAH · Not Marketed
SAIZEN 1.33MG VIAL1.33 mgPowder and solvent for solution for injection · Subcutaneous use1 VialSAR 101.35Biological · PrescriptionSERONOWithdrawn by MAH · Not Marketed
SAIZEN 8MG CLICK EASY8 mgPowder and solvent for solution for injection · Intravenous use1 VialSAR 833.15Biological · PrescriptionSERONOWithdrawn by MAH · Not Marketed
Indications — CHI Daman Drug Formulary

ADULT GROWTH HORMONE DEFICIENCY; CHILD GROWTH HORMONE DEFICIENCY; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDERS

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
HUMATROPE5MG/VIAL; 6MG/VIAL; 12MG/VIAL; 24MG/VIALinjectable · injectionLILLYPrescription16 Oct 1986
ZOMACTON5MG/VIAL; 10MG/VIALinjectable · injectionFERRINGPrescription25 May 1995
GENOTROPIN PRESERVATIVE FREE0.2MG/VIAL; 0.4MG/VIAL; 0.6MG/VIAL; 0.8MG/VIAL; 1MG/VIAL; 1.2MG/VIAL; 1.4MG/VIAL; 1.6MG/VIAL; 1.8MG/VIAL; 2MG/VIALinjectable · injectionPHARMACIAPrescription24 Aug 1995
GENOTROPIN5.8MG/VIAL; 13.8MG/VIALinjectable · injectionPHARMACIAPrescription24 Aug 1995
NUTROPIN AQ NUSPIN5MG/2ML (2.5MG/ML); 20MG/2ML (10MG/ML); 10MG/2ML (5MG/ML)injectable · injectionGENENTECHPrescription29 Dec 1995
SEROSTIM6MG/VIAL; 5MG/VIAL; 4MG/VIALinjectable · injectionEMD SERONOPrescription23 Aug 1996
SAIZEN5MG/VIAL; 8.8MG/VIALinjectable · injectionEMD SERONOPrescription8 Oct 1996
NORDITROPIN FLEXPRO5MG/1.5ML; 10MG/1.5ML; 15MG/1.5ML; 30MG/3MLinjectable · injectionNOVO NORDISK INCPrescription20 Jun 2000
OMNITROPE5.8MG/VIAL; 1.5MG/VIAL; 5MG/1.5ML; 10MG/1.5MLinjectable · injectionSANDOZPrescription30 May 2006
HUMATROPE2MG/VIALinjectable · injectionLILLYDiscontinued16 Oct 1986
NUTROPIN5MG/VIAL; 10MG/VIALinjectable · injectionGENENTECHDiscontinued17 Nov 1993
BIO-TROPIN4.8MG/VIALinjectable · injectionFERRINGDiscontinued25 May 1995
GENOTROPIN PRESERVATIVE FREE1.5MG/VIALinjectable · injectionPHARMACIADiscontinued24 Aug 1995
NUTROPIN AQ10MG/2ML (5MG/ML)injectable · injectionGENENTECHDiscontinued29 Dec 1995
NUTROPIN AQ PEN10MG/2ML (5MG/ML); 20MG/2ML (10MG/ML)injectable · injectionGENENTECHDiscontinued29 Dec 1995
SEROSTIM8.8MG/VIALinjectable · injectionEMD SERONODiscontinued23 Aug 1996
SEROSTIM LQ6MG/0.5ML (6MG/0.5ML)injectable · subcutaneousEMD SERONODiscontinued23 Aug 1996
SAIZEN6MG/VIAL; 4MG/VIALinjectable · injectionEMD SERONODiscontinued8 Oct 1996
NORDITROPIN5MG/1.5ML; 10MG/1.5ML; 15MG/1.5MLinjectable · injectionNOVO NORDISK INCDiscontinued20 Jun 2000
NORDITROPIN NORDIFLEX5MG/1.5ML; 10MG/1.5ML; 15MG/1.5ML; 30MG/3MLinjectable · injectionNOVO NORDISK INCDiscontinued20 Jun 2000
ACCRETROPIN5MG/ML (5MG/ML)injectable · injectionEMERGENTDiscontinued23 Jan 2008

EMA European Union — centrally authorised medicines

NutropinAq Ipsen Pharma · Authorised · authorised 15 Feb 2001 · ATC H01AC01

Therapeutic indication (EMA)

Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. Long-term treatment of growth failure associated with Turner syndrome. Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment.

Omnitrope Sandoz GmbH · Authorised · authorised 12 Apr 2006 · ATC H01AC01

Therapeutic indication (EMA)

Infants, children and adolescents Growth disturbance due to insufficient secretion of growth hormone (GH). Growth disturbance associated with Turner syndrome. Growth disturbance associated with chronic renal insufficiency. Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later. Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing. Adults Replacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict.

Valtropin BioPartners GmbH · Withdrawn · authorised 24 Apr 2006 · ATC H01AC01

Therapeutic indication (EMA)

Paediatric poulation Long-term treatment of children (2 to 11 years old) and adolescents (12 to 18 years old) with growth failure due to an inadequate secretion of normal endogenous growth hormone. Treatment of short stature in children with Turner syndrome, confirmed by chromosome analysis. Treatment of growth retardation in pre-pubertal children with chronic renal insufficiency. Adult patients Replacement therapy in adults with pronounced growth hormone deficiency of either childhood- or adult-onset aetiology. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated growth hormone deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like growth factor-1 (IGF-1) concentrations (< 2 standard deviation score (SDS)), who may be considered for one test. The cut-off point of the dynamic test should be strict.

Somatropin Biopartners BioPartners GmbH · Lapsed · authorised 5 Aug 2013 · ATC H01AC01

Therapeutic indication (EMA)

Somatropin Biopartners is indicated for the replacement therapy of endogenous growth hormone in adults with childhood- or adult-onset growth-hormone deficiency (GHD). Adult-onset: Patients with GHD in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone excluding prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a GHD. Childhood-onset: In patients with childhood-onset isolated GHD (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be performed after completion of growth, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (< -2 standard-deviation score (SDS)), who may be considered for one test. The cut-off point of the dynamic test should be strict.

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
GENOTROPIN024017035.3 MG / PENPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN0240171112 MG / PENPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024017460.2 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024017540.4 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024017620.6 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024017700.8 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024017891 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024017971.2 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024018001.4 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024018191.6 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024018271.8 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
GENOTROPIN024018352 MG / SYRPOWDER FOR SOLUTION · SUBCUTANEOUSPFIZER CANADA ULC
NORDITROPIN FLEXPRO0252920310 MG / 1.5 MLSOLUTION · SUBCUTANEOUSNOVO NORDISK CANADA INC
NORDITROPIN FLEXPRO0252921115 MG / 1.5 MLSOLUTION · SUBCUTANEOUSNOVO NORDISK CANADA INC
OMNITROPE023250635 MG / 1.5 MLSOLUTION · SUBCUTANEOUSSANDOZ CANADA INCORPORATED
OMNITROPE0232507110 MG / 1.5 MLSOLUTION · SUBCUTANEOUSSANDOZ CANADA INCORPORATED
OMNITROPE0245964715 MG / 1.5 MLSOLUTION · SUBCUTANEOUSSANDOZ CANADA INCORPORATED
SAIZEN022379715 MG / VIALPOWDER FOR SOLUTION · SUBCUTANEOUS; INTRAMUSCULAREMD SERONO, A DIVISION OF EMD INC., CANADA
SAIZEN023501225.83 MG / MLSOLUTION · SUBCUTANEOUSEMD SERONO, A DIVISION OF EMD INC., CANADA
SAIZEN023501308 MG / MLSOLUTION · SUBCUTANEOUSEMD SERONO, A DIVISION OF EMD INC., CANADA
SAIZEN023501498 MG / MLSOLUTION · SUBCUTANEOUSEMD SERONO, A DIVISION OF EMD INC., CANADA

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACGENOTROPIN 12 MG CARTRIDGE$1810.40353per EA1 Jan 2026
US NADACGENOTROPIN 5 MG CARTRIDGE$752.224per EA23 Sep 2026
US NADACNORDITROPIN FLEXPRO 10 MG/1.5$1136.45556per ML23 Sep 2026
US NADACNORDITROPIN FLEXPRO 15 MG/1.5$1704.64417per ML23 Sep 2026
US NADACNORDITROPIN FLEXPRO 5 MG/1.5$570.77429per ML23 Sep 2026
US NADACOMNITROPE 5 MG/1.5 ML CRTG$430.36341per ML1 Jan 2026
US NADACOMNITROPE 5.8 MG VIAL$326.24846per EA23 Sep 2026
US NADACZOMACTON 10 MG VIAL$556.824per EA19 Aug 2026
US NADACZOMACTON 5 MG VIAL$278.604per EA23 Sep 2026
NHS Drug TariffSomatropin (epr) 10mg/1.5ml solution for injection pre-filled disposable devices£212.701 pre-filled disposable injection1 Oct 2026
NHS Drug TariffSomatropin (epr) 15mg/1.5ml solution for injection pre-filled disposable devices£319.051 pre-filled disposable injection1 Oct 2026
NHS Drug TariffSomatropin (rbe) 1.2mg powder and solvent for solution for injection pre-filled disposable devices£146.067 pre-filled disposable injection1 Oct 2026
NHS Drug TariffSomatropin (rbe) 1.4mg powder and solvent for solution for injection pre-filled disposable devices£170.397 pre-filled disposable injection1 Oct 2026
NHS Drug TariffSomatropin (rbe) 1.6mg powder and solvent for solution for injection pre-filled disposable devices£194.747 pre-filled disposable injection1 Oct 2026
NHS Drug TariffSomatropin (rbe) 1.8mg powder and solvent for solution for injection pre-filled disposable devices£219.087 pre-filled disposable injection1 Oct 2026
NHS Drug TariffSomatropin (rbe) 10mg/1.5ml solution for injection cartridges£737.495 cartridge1 Oct 2026
NHS Drug TariffSomatropin (rbe) 12mg powder and solvent for solution for injection cartridges£208.651 cartridge1 Oct 2026
NHS Drug TariffSomatropin (rbe) 12mg powder and solvent for solution for injection pre-filled disposable devices£208.651 pre-filled disposable injection1 Oct 2026
NHS Drug TariffSomatropin (rbe) 15mg/1.5ml solution for injection cartridges£1106.225 cartridge1 Oct 2026
NHS Drug TariffSomatropin (rbe) 1mg powder and solvent for solution for injection pre-filled disposable devices£121.717 pre-filled disposable injection1 Oct 2026
NHS Drug TariffSomatropin (rbe) 200microgram powder and solvent for solution for injection pre-filled disposable devices£24.357 pre-filled disposable injection1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

All safety entries for somatropin →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.